October 22, 2014
CLEVELAND, OH – GenomOncology today announced that Manuel Glynias, the company’s President and CEO, will be presenting a corporate overview at the Cleveland Clinic’s 2014 Medical Innovation Summit to be held October 26-29 in Cleveland, OH.
The presentation will take place on Wednesday October 29 at 8:25 ET at the Cleveland Convention Center in Room 26. There will be a breakout for Q&A immediately following the presentation in Room 23.
GenomOncology is focused on enabling precision medicine by translating next generation sequencing data into actionable information for clinicians and researchers. The company’s proprietary technology platform, GO Clinical Workbench, streamlines the use of NGS data in conjunction with other analytic modalities and allows clinical laboratories to produce an actionable clinical report using the molecular profile of an individual patient’s tumor.
“I was pleased to be invited to participate in the Cleveland Clinic’s Medical Innovation Summit,” commented Manuel Glynias. “Translating the vast amounts of data from next-generation sequencing into useful information for clinical use is of the utmost importance. GenomOncology is dedicated to expanding the availability of this information to the industry and welcomes the opportunity to share ideas with conference attendees.”
Mr. Glynias is a serial entrepreneur with over 25 years of experience in bioinformatics. Immediately prior to GenomOncology, Manuel was a partner at Rosetta, a leading interactive marketing agency, where he helped develop big data solutions for ecommerce clients. In the late 90’s, Manuel was the founder and CEO of NetGenics, a venture-backed provider of discovery informatics to the biopharmaceutical industry and academic research centers. He also developed a number of other commercial software platforms including MacGene, Gene Works, and Primer Express. Manuel has an AB in Biochemistry and Molecular Biology from Harvard College.
The summit will convene over 1,500 great thinkers and leaders for a candid exchange on new medical technology, its future, recent breakthroughs and continuing challenges.
The Trout Group [www.troutgroup.com] has teamed up with The Cleveland Clinic to create Ground Waves – an exciting two-day showcase that will present a wide array of companies making waves in cancer treatment and personalized medicine. The Summit is renowned for thought-provoking panels, lively 1-on-1 discussions with influential CEOs, and the discovery of the latest market-ready technologies poised to shake up the status quo.
The full summit agenda is available at http://summit.clevelandclinic.org
GenomOncology is enabling precision medicine by translating next generation sequencing data into actionable information for clinicians and researchers. In collaboration with molecular pathologists and physicians, GenomOncology has developed the GO Clinical Workbench™, a decision support tool with a step-by-step workflow that takes raw data from the sequencer and translates the specific molecular profile of each patient’s tumor genome into an actionable clinical report. GenomOncology’s research platform, GenomAnalytics™, allows scientists to analyze one or hundreds of genomes simultaneously to look for causal variants, reducing the time required to understand the genomic alterations that lead to new discoveries about the biology of cancer. More information can be found on the company’s website at www.genomoncology.com.